

**EISAI'S ANTICANCER AGENT HALAVEN® NEWLY APPROVED IN JAPAN  
FOR TREATMENT OF SOFT TISSUE SARCOMA**

**[Notes to editors]**

**1. Product Outline (New Information Related to Additional Indication Underlined)**

1) Product name

Halaven<sup>®</sup> Injection 1 mg

2) Generic name

Eribulin mesylate

3) Indication for use

Inoperable or recurrent breast cancer, soft tissue sarcoma

4) Dosage and administration

The usual adult dose of eribulin mesylate is 1.4 mg/m<sup>2</sup> body surface area, administered intravenously as a single dose over 2 to 5 minutes, once a week. Treatment

#### **4. About Study 309<sup>1</sup>**

Conducted primarily in Europe and the United States, Study 309 was a multicenter, open-